By Pushkala Aripaka and Bhanvi Satija Jan 20 (Reuters) - Britain's GSK has agreed to buy RAPT Therapeutics for $2.2 billion, ...

About 1 in 5 patients with confirmed amoxicillin allergy show cross-reactivity with piperacillin-tazobactam, researchers find ...

The growing scourge of food allergies drove U.K. heavyweight GSK to announce a $2.2 billion deal on Tuesday.

GSK will acquire RAPT Therapeutics for $2.2 billion to gain ozureprubart, a promising food allergy drug that could treat over ...

The likelihood for penicillin allergy delabeling was significantly reduced among Black and Asian patients vs. white patients, ...

HKeyBio, a preclinical CRO focused on autoimmune and allergic disease drug development, today announced a translational preclinical strategy, HKEY-AIRxTM1.0  designed to address one of the most persis ...

HKeyBio, a preclinical CRO focused on autoimmune and allergic disease drug development, announced HKEY-AIRx1.0, a translational preclinical ...

The challenge, made popular on social media site TikTok, involves ingesting large amounts of over-the-counter medicine.

That price equates to an aggregate equity value of $2.2 billion, according to GSK, who added that the upfront investment net ...

The Law of Mass action predicts that all adverse drug reactions are related to the concentration of the drug at the site of ...

A food manufacturer is recalling a fish ball product sold online and through distributors in 13 states.

GSK is staking billions on a new way to protect people from life‑threatening food allergies, agreeing to buy RAPT Therapeutics in a deal that values the California biotech at more than two billion ...